Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 9/20 | 0.43 |
| ▸ | DHFR | P00374 | 5/20 | 0.43 |
| ▸ | TYMS | P04818 | 2/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4093607 | 0.85 | DHFR (0.42) | LRRK2DHFRTYMSEGFRKDR | |
| SCHEMBL4093485 | 0.85 | DHFR (0.46) | LRRK2DHFRTYMSEGFRKDR | |
| SCHEMBL4093475 | 0.81 | NPC1 (0.43) | LRRK2DHFRTYMSEGFRKDR | |
| SCHEMBL14642116 | 0.79 | DHFR (0.42) | LRRK2DHFRTYMSEGFRKDR | |
| SCHEMBL4091846 | 0.77 | HSP90AA1 (0.55) | DHFRTYMSEGFRKDRHSP90AA1 | |
| SCHEMBL4085848 | 0.77 | EGFR (0.45) | LRRK2DHFRTYMSEGFRKDR | |
| SCHEMBL4086287 | 0.77 | DHFR (0.40) | LRRK2DHFRTYMSEGFRKDR | |
| SCHEMBL4093637 | 0.77 | MAOB (0.48) | LRRK2DHFRTYMSEGFRKDR | |
| SCHEMBL4086671 | 0.76 | DHFR (0.39) | LRRK2DHFRTYMSEGFRKDR | |
| SCHEMBL4094840 | 0.76 | DHFR (0.39) | LRRK2DHFRTYMSEGFRKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2036895-B9 | HSP90 INHIBITOR | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2013-07-10 | — | — | EP | claimed |
| EP-2036895-B1 | HSP90 INHIBITOR | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2013-01-16 | — | — | EP | claimed |
| US-20090247524-A1 | HSP90 Inhibitor | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-10-01 | — | — | US | claimed |
| EP-2036895-A1 | HSP90 INHIBITOR | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-03-18 | — | — | EP | claimed |
| EP-2036895-B9 | HSP90 INHIBITOR | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2013-07-10 | — | — | EP | disclosed |
| EP-2036895-B1 | HSP90 INHIBITOR | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-8193351-B2 | HSP90 inhibitor | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-06-05 | — | — | US | disclosed |
| US-8193351-B2 | HSP90 inhibitor | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-06-05 | — | — | US | disclosed |
| US-8193351-B2 | HSP90 inhibitor | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-06-05 | — | — | US | disclosed |
| US-20090247524-A1 | HSP90 Inhibitor | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-10-01 | — | — | US | disclosed |
| US-20090247524-A1 | HSP90 Inhibitor | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-10-01 | — | — | US | disclosed |
| US-20090247524-A1 | HSP90 Inhibitor | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-10-01 | — | — | US | disclosed |
| EP-2036895-A1 | HSP90 INHIBITOR | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-03-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247524-A1 | HSP90 Inhibitor | HSP90AB1, HSP90B1, HSP90AA1 | LRRK2 898/4885DHFR 1834/4885TYMS 3232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.